Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more
Mega Lifesciences Public Company Limited (MEGA-R) - Total Liabilities
Latest total liabilities as of June 2025: ฿4.37 Billion THB
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has total liabilities worth ฿4.37 Billion THB as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mega Lifesciences Public Company Limited - Total Liabilities Trend (2010–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mega Lifesciences Public Company Limited Competitors by Total Liabilities
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Webjet Limited
PINK:WEBJF
|
USA | $1.10 Billion |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
USA | $319.82 Million |
|
Beijing InterAct Technology Co Ltd
SHE:300419
|
China | CN¥245.56 Million |
|
Philex Mining Corporation
PINK:PXMFF
|
USA | $22.93 Billion |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
China | CN¥2.49 Billion |
|
Shanghai Fudan Forward S&T Co Ltd
SHG:600624
|
China | CN¥872.43 Million |
|
Origin Enterprises plc
PINK:ORENF
|
USA | $1.04 Billion |
|
UCO Bank
NSE:UCOBANK
|
India | ₹3.34 Trillion |
Liability Composition Analysis (2010–2024)
This chart breaks down Mega Lifesciences Public Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mega Lifesciences Public Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mega Lifesciences Public Company Limited (2010–2024)
The table below shows the annual total liabilities of Mega Lifesciences Public Company Limited from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ฿4.33 Billion | -16.94% |
| 2023-12-31 | ฿5.22 Billion | -11.12% |
| 2022-12-31 | ฿5.87 Billion | +11.88% |
| 2021-12-31 | ฿5.25 Billion | +13.79% |
| 2020-12-31 | ฿4.61 Billion | +5.81% |
| 2019-12-31 | ฿4.36 Billion | +11.50% |
| 2018-12-31 | ฿3.91 Billion | +12.45% |
| 2017-12-31 | ฿3.48 Billion | +6.57% |
| 2016-12-31 | ฿3.26 Billion | -0.51% |
| 2015-12-31 | ฿3.28 Billion | +19.45% |
| 2014-12-31 | ฿2.74 Billion | -3.49% |
| 2013-12-31 | ฿2.84 Billion | +13.32% |
| 2012-12-31 | ฿2.51 Billion | +27.26% |
| 2011-12-31 | ฿1.97 Billion | +43.82% |
| 2010-12-31 | ฿1.37 Billion | -- |